Workshop and Q&A October 6th

Strain identifier

BacDive ID: 130712

Type strain: Yes

Species: Streptomyces cyslabdanicus

Strain Designation: K04-0144

Culture col. no.: DSM 42135, NBRC 110081

Strain history: <- A. Matsumoto, Kitasato Universitiy. Tokyo; K04-0144

NCBI tax ID(s): 1470456 (species)

« Browse strain by BacDive ID »

expand / minimize allblue arrow down

Exclude non-curated data/information

Streptomyces cyslabdanicus K04-0144 is a mesophilic bacterium that was isolated from soil collected under a tree.

  1. mesophilic
  2. 16S sequence
  3. Bacteria
  • Availability in culture collections External linksarrow_down
  • [Ref.: #21945] Culture collection no. DSM 42135, NBRC 110081
    Titlearrow to sort Authorsarrow to sort Journalarrow to sort DOIarrow to sort Yeararrow to sort Mesharrow to sort Topicarrow to sort Topic2arrow to sort
    Streptomyces lactacystinicus sp. nov. and Streptomyces cyslabdanicus sp. nov., producing lactacystin and cyslabdan, respectively. Take A, Matsumoto A, Omura S, Takahashi Y J Antibiot (Tokyo) 10.1038/ja.2014.162 2014 Acetylcysteine/*analogs & derivatives/metabolism, Anti-Bacterial Agents/*metabolism, DNA, Bacterial/genetics, Diterpenes/*metabolism, Gene Expression Regulation, Bacterial/physiology, Phylogeny, Species Specificity, Streptomyces/*classification/*metabolism/ultrastructure Phylogeny Metabolism *
    Biosynthesis of mercapturic acid derivative of the labdane-type diterpene, cyslabdan that potentiates imipenem activity against methicillin-resistant Staphylococcus aureus: cyslabdan is generated by mycothiol-mediated xenobiotic detoxification. Ikeda H, Shin-Ya K, Nagamitsu T, Tomoda H J Ind Microbiol Biotechnol 10.1007/s10295-015-1694-6 2015 Acetylcysteine/*analogs & derivatives/chemistry/metabolism/pharmacology, Amidohydrolases/genetics/metabolism, Biosynthetic Pathways/genetics, Cysteine/*metabolism, Diterpenes/*chemistry/*metabolism/*pharmacology, Glycopeptides/*metabolism, Imipenem/*pharmacology, Inactivation, Metabolic, Inositol/*metabolism, Methicillin-Resistant Staphylococcus aureus/*drug effects, Multigene Family/genetics, Mycelium/metabolism, Organophosphates/metabolism, Streptomyces/genetics/metabolism, Xenobiotics/*metabolism Metabolism Pathogenicity *
    New Approaches to Drug Discovery for Combating MRSA. Tomoda H Chem Pharm Bull (Tokyo) 10.1248/cpb.c15-00743 2016 Anti-Bacterial Agents/chemistry/isolation & purification/*pharmacology, *Drug Discovery, Humans, Methicillin-Resistant Staphylococcus aureus/*drug effects/growth & development, Microbial Sensitivity Tests, Molecular Structure, Streptococcal Infections/*drug therapy/*microbiology Pathogenicity Enzymology *

Change proposal

You found an error in BacDive? Please tell us about it!

Note that changes will be reviewed and judged. If your changes are legitimate, changes will occur within the next BacDive update. Only proposed changes supported by the according reference will be reviewed. The BacDive team reserves the right to reject proposed changes.

Field you want to change:

CAPTCHAReload captcha

Change proposal

Successfully sent